Sigma Planning’s CorMedix CRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$247K Buy
32,142
+2,531
+9% +$20.3K 0.01% 1141
2026
Q2
$232K Sell
29,611
-5,309
-15% -$41.9K 0.01% 1242
2026
Q1
$237K Buy
34,920
+11,048
+46% +$81.7K 0.01% 1154
2025
Q4
$278K Sell
23,872
-2,759
-10% -$30.5K 0.01% 1069
2025
Q3
$310K Sell
26,631
-737
-3% -$8.91K 0.01% 1024
2025
Q2
$337K Sell
27,368
-8,937
-25% -$98.7K 0.01% 950
2025
Q1
$224K Buy
36,305
+2,612
+8% +$27K 0.01% 1080
2024
Q4
$273K Sell
33,693
-6,254
-16% -$62.5K 0.01% 968
2024
Q3
$323K Buy
39,947
+7,679
+24% +$41.6K 0.01% 931
2024
Q2
$140K Buy
32,268
+944
+3% +$4.8K ﹤0.01% 1120
2024
Q1
$133K Buy
+31,324
New +$109K ﹤0.01% 1169

Other funds holding CRMD

Sigma Planning's CRMD Position: Q3 2026 in Review

Sigma Planning increased its CorMedix (CRMD) stake by 8.5% in Q3 2026, buying an estimated $20.3K and bringing the position to 32,142 shares worth $247K. The position accounts for 0.01% of the portfolio, ranked #1141.

Sigma Planning first reported a position in CRMD in Q1 2024 and has held it in 11 quarters since. The position peaked at $337K in Q2 2025. 144 funds tracked by Wall St. Rank hold CRMD as of Q3 2026.

  • Sigma Planning held 32,142 shares of CorMedix worth $247K as of Q3 2026.
  • Sigma Planning bought 2,531 CorMedix shares in Q3 2026, an estimated $20.3K.
  • CorMedix made up 0.01% of Sigma Planning's portfolio in Q3 2026, its #1141 holding.
  • Sigma Planning first reported a position in CorMedix in Q1 2024 and has held it in 11 quarters since.
  • Sigma Planning's CorMedix position peaked at $337K in Q2 2025.
  • 144 funds tracked by Wall St. Rank held CorMedix as of Q3 2026.

Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.